8-K

­­­­­­­­­­­­­­­­­­­­UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

September 9, 2010

(Date of the earliest event reported)

Simulations Plus, Inc.

(Exact name of registrant as specified in its charter)

California	001-32046	95-4595609
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

42505 10th Street West, Lancaster, California 93534-7059

(Address of principal executive offices) (Zip Code)

661-723-7723

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On September 9, 2010, Simulations Plus, Inc., a California corporation (the "Company"), issued a press release announcing that Walter S. Woltosz, the Company’s chairman of the board, CEO and president, will present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2010.  A copy of the press release and presentation material are attached hereto as Exhibit 99.1 and 99.2 and are incorporated herein by reference.

This report on Form 8-K (the "Report"), including the disclosures set forth herein, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms "anticipates," "expects," "estimates," "believes" and similar expressions, as they relate to us or our management, are intended to identify such forward-looking statements.

Forward-looking statements in this Report or hereafter, including in other publicly available documents filed with the Securities and Exchange Commission (the "Commission"), reports to the stockholders of Simulations Plus, Inc., a California corporation (the "Company" or "us," "our" or "we") and other publicly available statements issued or released by us involve known and unknown risks, uncertainties and other factors which could cause our actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. Such future results are based upon management's best estimates based upon current conditions and the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents filed with the Commission, each of which could adversely affect our business and the accuracy of the forward-looking statements contained herein. Our actual results, performance or achievements may differ materially from those expressed or implied by such forward-looking statements.

Item 9.01 Financial Statements and Exhibits

(c)           Exhibits

99.1  Press Release dated September 9, 2010.

99.2  Power Point Presentation on September 13, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	SIMULATIONS PLUS, INC.
Dated: September 13, 2010	By:	/s/ Momoko Beran
		Momoko Beran
		Chief Financial Officer

EX-99.1

Exhibit 99.1

Simulations Plus to Present at the Rodman & Renshaw Annual Global Investment Conference

Leading Provider of Simulation and Modeling Software for Pharmaceutical Discovery and Development Scheduled to Present on September 13, 2010

Rodman & Renshaw Annual Global Investment Conference NYC

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that Walter S. Woltosz, the Company's chairman of the board, CEO and president, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:05 p.m. (ET) on September 13, 2010. The conference will be held September 12-15, 2010, at the New York Palace Hotel, 455 Madison Avenue, New York, NY. Mr. Woltosz will be available during the day on September 13 for one-on-one meetings. Please contact your Rodman & Renshaw representative to schedule a meeting.

Mr. Woltosz will discuss the Company’s operational results, growth strategy, and its technologies. The Company recently reported preliminary fiscal 2010 (ended August 31) revenues of $10.71 million, a new record fiscal year, which included approximately 20% 4th quarter revenue growth for both its pharmaceutical software business and the Words+ subsidiary. The combination of aggressive marketing and sales programs for the pharmaceutical software and services business, including product updates and new product launches, along with the new EyePro eyegaze system that was released in May by the Words+ subsidiary, has resulted in the strong growth despite the overall economy.

Investors and other interested parties may access the live presentation athttp://www.wsw.com/webcast/rrshq18/slp/.

About Simulations Plus, Inc.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide, as well as a personal productivity tool for the mass market called Abbreviate!™, and an educational software series for science students in middle and high schools known as FutureLab™. Our wholly owned subsidiary, Words+, Inc., provides assistive technologies to persons with disabilities, including the communication system used by world-famous theoretical astrophysicist, Profe ssor Stephen Hawking, of the University of Cambridge. For more information, visit our Web sites at www.simulations-plus.com and www.words-plus.com.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improv ed versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the Securities and Exchange Commission.

Contacts

Simulations Plus Investor Relations

Ms. Renée Bouché, 661-723-7723


renee@simulations-plus.com
or

Hayden IR

Cameron Donahue, 651-653-1854


Cameron@haydenir.com

Source: Simulations Plus, Inc.

EX-99.2

Exhibit 99.2

Simulations Plus, Inc.

(NASDAQ:SLP)

September 2010

With the exception of historical information, the matters discussed in this
presentation are forward looking statements that involve a number of risks
and uncertainties. The actual results of the Company could differ
significantly from those statements. Factors that could cause or contribute
to such differences include, but are not limited to: continuing demand for
the Company’s products, competitive factors, the Company’s ability to
finance future growth, the Company’s ability to produce and market new
products in a timely fashion, the Company’s ability to continue to attract
and retain skilled personnel, and the Company’s ability to sustain or
improve current levels of productivity. Further information on the
Company’s risk factors is contained in the Company’s quarterly and
annual reports and filed with the Securities and Exchange Commission.

Safe Harbor Statement

SLP Q4FY10 and FY 2010 Highlights
Three months and fiscal year ended 8/31/10

•12th consecutive profitable quarter

•Record fourth quarter:

–4QFY10 sales up 20% to record $2.2 million from $1.8
million in 4QFY09

–Pharmaceutical software and services sales increase
20.5% for 4QFY10 over 4QFY09

–Recurring revenue from annual pharmaceutical
software licenses $1.67 million for 3QFY10

–Words+ subsidiary revenues increase 19.4%for
4QFY10 over 4QFY09

•Record fiscal year:

–FY10 sales up (17.2%) to record $10.7 millionfrom
$9.1 million in FY09

–Pharmaceutical software and services sales increase
20.9% for FY10 over FY09

–Words+ subsidiary revenues increase 8.9% for FY10
over FY09

•Strong balance sheet:

–$9.5 million in cash at 08/31/10 and no debt

•Increase of $2.0 million (26.7%) over 8/31/09 after stock repurchases
of approximately $0.75 million

Professor Stephen Hawking

•One of world’s foremost
theoretical astrophysicists -
author of best-seller “A Brief
History of Time”

•Paralyzed with Lou Gehrig’s
disease (ALS)

•Has used Words+ software
since 1985 for speaking,
writing, Internet access,
environmental control

EyePro™ Eyegaze Input System

•Words+ subsidiary
launched new EyePro
eyegaze product in May
with immediate sales
during Q4.

•Fills gap in product line
that had previously
limited our sales to a
major market segment

•Can be added to any
Windows-based
computer or
communication device

Consolidated Revenue

Record 1st quarter

Record 4th quarter

4Q10E includes preliminary Q4 revenues

(fiscal year end is August 31)

Revenue History for 5 Fiscal Years

2010 includes preliminary
Q4 results (fiscal year end
is August 31)

Pharmaceutical Growth

4Q10E includes preliminary Q4 revenues

(fiscal year end is August 31)

Pharmaceutical Growth
(through 3Q: 4Q income available after audit)

Consolidated Gross Margin (through 3Q)(through 3Q: 4Q results available after audit)

75.6%

78.9%

78.8%

70.4%

73.8%

74.4%

80.0%

67.9%

75.0%

76.3%

77.6%

Income Before Taxes
(through 3Q: 4Q results available after audit)

Net Income by Business Unit
(through 3Q: 4Q results available after audit)

Consolidated Income Statement

(through 3Q: 4Q results available after audit)

($ millions)

	Q3 FY 10	Q3 FY 09	YTD FY 10	YTDFY 09
Pharmaceutical software and services revenue	2.325	1.986	6.287	5.194
Words+ revenue	0.794	0.728	2.219	2.110
Consolidated revenue	3.119	2.714	8.506	7.304
Gross profit	2.420	2.131	6.499	5.535
Gross profit margin	77.6%	78.5%	76.4%	75.8%
SG&A	1.118	0.989	3.211	2.930
R&D	0.234	0.294	0.748	0.849
Total operating expenses	1.352	1.283	3.959	3.779
Income before income taxes	1.112	0.888	2.747	1.900
Net income	0.740	0.569	1.811	1.249
Earnings per share (diluted)	0.04	0.03	0.11	0.07

Select Balance Sheet Items

(through 3Q: 4Q results available after audit)

($ millions)

	May 31, 2010	Aug. 31, 2009
Cash and cash equivalents*	$8.583	$7.473
Total current assets	12.335	10.265
Total assets	$14.566	$12.303
Total current liabilities	1.342	0.937
Total liabilities	1.775	1.732
Shareholders’ equity	12.791	10.571
Total liabilities and shareholders’        equity**	$14.566	12.303

*14.9% increase in first 3 quarters

**18.4% increase in first 3 quarters

Share Repurchase Program

•The board of directors approved a second share repurchase
program beginning February 2010 for one year

•The purpose of the program is to use some of our excess
cash to increase shareholder value by reducing the number
of shares outstanding and increasing the per-share metrics
(EPS, sales/share, etc.)

•The program authorizes repurchase of up to 1,000,000
shares during that time frame

•As of August 31, the company has repurchased a total of
320,409 shares at an average price of $2.33

•Although we are authorized to continue repurchasing
shares, the company does not announce when or if further
repurchases may be made, nor a price range for such
repurchases

Aggressive Marketing and Sales Program

•More of our development and consulting
scientists are involved in covering the
expanded conference/meeting schedule

•The number of conferences and scientific
meetings continues at a high level, with 15
in the 3rd quarter and 13 in the 4th quarter

•Fundamental industry shift underway

–Pharma increasingly utilizing simulation software and
modeling tools to increase productivity

–Software tools are always evolving, and as the
technology advances, new capabilities attract new users,
such as the ocular and nasal/pulmonary delivery
capabilities in the newly launched GastroPlus 7.0

–Consulting services continue to grow

–Marketing and sales emphasis on our consulting
capabilities is paying off

–Repeat Big 5 customers are evidence of the quality of our
consulting services

Discovery

Preclinical

Clinical

MedChem Studio™

GastroPlus™DDDPlus™

ADMET Predictor™

Software for Pharmaceutical R&D

Cutting-edge Software Enhancements

•Simulations Plus continues to increase its technological advantage

•Version 7.0 released in August

•Three new market-expanding capabilities:

•Drug-drug interaction

•Ocular drug delivery

•Nasal/pulmonary drug delivery

•Version 5.0 released in July - new toxicity models, all models retrained
with latest ionization descriptors and charge descriptors

•SBIR grant funding supporting further improvements

•Prediction of sites of metabolism in development

•Major enhancements to graphical user interface in development version

•Significant speed improvements achieved in development version

•Released as MedChem Studio (formerly ClassPharmer™) in August

•Stable product with fine-tuning of capabilities

•Growing customer base shows gradual acceptance of this unique
technology

•Flagship product: the industry’s Gold Standard - most advanced simulation
of oral absorption/pharmacokinetics/pharmacodynamics

•FDA has numerous licenses, also NIHS in Japan

•Strategy going forward:

–Continue extending product capabilities:

•Version 7.0 released in August with significant market-expanding capabilities:

•New routes of administration (ocular, intranasal, pulmonary)

•Drug-drug interactions for metabolic interactions

•Drug-drug interactions for transporters as well as enzymes

•Transdermal delivery

–Initiating training courses as new profit center - October start

•Industry needs advanced training

GastroPlusTM

•Version 5.0 released in July with major upgrades and new models

•Ranked #1 in accuracy in every independent comparison study

–No other company has consistently been in the top 4!

•Predicts numerous properties of molecules from just their structures, including
physicochemical and pharmacokinetic properties and over 20 potential toxicities

•Strategy going forward:

–Continue to expand number of predictions (e.g., metabolism, toxicity)

–Partnership with FDA in approval process now for additional toxicity models

–Continuously improve prediction accuracy through better molecular descriptors

–Over $600K in SBIR grants awarded to improve descriptors used in models

ADMET PredictorTM

Solubility

Permeability

logP

Ionization/pKa

Toxicities

Metabolism

HIV-1 activity

etc.

•Formerly ClassPharmer™ - merge of two products acquired in 2005

•Classifies molecules by “common substructures” using proprietary algorithms

•powerful data mining tool for high throughput screening data

•Helps chemists identify what it is about molecular structures that cause good or bad properties

•Designs new molecules using proprietary algorithms to eliminate “losers”

•Tight integration with ADMET Predictor provides multidimensional filtering capability

•Strategy going forward:

–New emphasis on molecule design capabilities - shift to multi-dimensional optimization

–Tighter integration with ADMET Predictor - each promotes sales of the other

–Focus on becoming the preferred tool for molecular design by pharmaceutical chemists

MedChem StudioTM

•First and only simulation tool for in vitro dissolution experiments

•Industry is learning how to use this unique tool and sales are increasing steadily

•FDA is one of our users

•Strategy going forward:

–Continue aggressive marketing and sales activities

•Educate formulation scientists on how to use simulation in their work

•Emphasize compatibility with GastroPlus for formulation studies

–Continue incremental improvements in response to customer requests

DDDPlusTM

Summary

•Simulations Plus is characterized by:

–Outstanding scientific reputation

•Top-rated software in independent comparison
studies

–GastroPlus

–ADMET Predictor

•Constant stream of consulting contracts, including
top 5 pharmaceutical companies

–Consistently strong financial performance

–Excellent balance sheet

•Growth strategies include both organic
and acquisition opportunities

Questions?